Sanofi
Tremor tracks 13 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- SNYSanofi0Calm
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Running, no new patientsPhase 3943 patientsMain results: Mar 24, 2028 - SNYSanofi0Calm
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Running, no new patientsPhase 264 patientsMain results: Apr 1, 2027 - SNYSanofi0Calm
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Signing up patientsPhase 1/2104 patientsMain results: Oct 13, 2027 - SNYSanofi0Calm
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Invite-only sign-upPhase 270 patientsMain results: Nov 30, 2028 - SNYSanofi0Calm
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Signing up patientsPhase 1/2258 patientsMain results: Sep 13, 2027 - SNYSanofi0Calm
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Running, no new patientsPhase 3531 patientsMain results: Nov 6, 2024 - SNYSanofi0Calm
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Running, no new patientsPhase 32,500 patientsMain results: Apr 30, 2029 - SNYSanofi0Calm
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
Signing up patientsPhase 230 patientsMain results: Aug 2, 2028 - SNYSanofi0Calm
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2542 patientsMain results: Jan 19, 2027 - SNYSanofi0Calm
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Running, no new patientsPhase 3475 patientsMain results: Apr 5, 2027 - SNYSanofi0Calm
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Running, no new patientsPhase 2118 patientsMain results: Dec 22, 2025 - SNYSanofi0Calm
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Running, no new patientsPhase 3337 patientsMain results: Oct 14, 2030 - SNYSanofi0Calm
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
FinishedPhase 31,131 patientsMain results: Aug 29, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 1 purchase
- SanofiLarge shareholder · Aug 6, 2026Bought 300,000 sharesabout $5.1 million ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.